APRE Aprea Therapeutics Inc
Price (delayed)
$1.92
Market cap
$10.54M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.35
Enterprise value
-$12.35M
Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor
Highlights
The company's gross profit has surged by 158% YoY and by 15% QoQ
Aprea Therapeutics's revenue has soared by 158% YoY and by 15% from the previous quarter
The quick ratio has grown by 38% YoY but it has contracted by 6% from the previous quarter
The equity has grown by 14% YoY but it has contracted by 12% from the previous quarter
Key stats
What are the main financial stats of APRE
Market
Valuations
Earnings
Shares outstanding
5.49M
Market cap
$10.54M
Enterprise value
-$12.35M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.54
Price to sales (P/S)
7.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-8.22
Revenue
$1.5M
Gross profit
$1.5M
Operating income
-$14.32M
Net income
-$12.96M
EBIT
-$14.25M
EBITDA
-$14.23M
Free cash flow
-$13.57M
Per share
Balance sheet
Liquidity
EPS
-$2.35
EPS diluted
-$2.35
Free cash flow per share
-$2.46
Book value per share
$3.55
Revenue per share
$0.27
TBVPS
$4.35
Total assets
$23.98M
Total liabilities
$4.67M
Debt
$0
Equity
$19.31M
Working capital
$20.22M
Debt to equity
0
Current ratio
7.01
Quick ratio
6.81
Net debt/EBITDA
1.61
Margins
Efficiency
Dividend
EBITDA margin
-946.7%
Gross margin
100%
Net margin
-862.4%
Operating margin
-953%
Return on assets
-45.5%
Return on equity
-54.1%
Return on invested capital
N/A
Return on capital employed
-69.1%
Return on sales
-948.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
APRE stock price
How has the Aprea Therapeutics stock price performed over time
Intraday
-5.88%
1 week
-12.33%
1 month
-24.22%
1 year
-69.76%
YTD
-41.64%
QTD
-5.88%
Financial performance
How have Aprea Therapeutics's revenue and profit performed over time
Revenue
$1.5M
Gross profit
$1.5M
Operating income
-$14.32M
Net income
-$12.96M
Gross margin
100%
Net margin
-862.4%
The company's gross profit has surged by 158% YoY and by 15% QoQ
Aprea Therapeutics's revenue has soared by 158% YoY and by 15% from the previous quarter
The net margin has surged by 65% year-on-year and by 16% since the previous quarter
The company's operating margin has surged by 64% YoY and by 15% QoQ
Growth
What is Aprea Therapeutics's growth rate over time
Valuation
What is Aprea Therapeutics stock price valuation
P/E
N/A
P/B
0.54
P/S
7.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-8.22
APRE's EPS is up by 41% year-on-year and by 16% since the previous quarter
APRE's P/B is 66% below its 5-year quarterly average of 1.7 and 37% below its last 4 quarters average of 0.9
The equity has grown by 14% YoY but it has contracted by 12% from the previous quarter
Aprea Therapeutics's revenue has soared by 158% YoY and by 15% from the previous quarter
APRE's P/S is 59% below its last 4 quarters average of 18.2
Efficiency
How efficient is Aprea Therapeutics business performance
APRE's return on sales has surged by 64% year-on-year and by 16% since the previous quarter
The company's return on equity rose by 18% YoY and by 7% QoQ
Aprea Therapeutics's ROA has increased by 13% YoY and by 5% from the previous quarter
Dividends
What is APRE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for APRE.
Financial health
How did Aprea Therapeutics financials performed over time
The quick ratio has grown by 38% YoY but it has contracted by 6% from the previous quarter
The current ratio has increased by 36% YoY but it has decreased by 3.7% from the previous quarter
The debt is 100% smaller than the equity
The equity has grown by 14% YoY but it has contracted by 12% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.